Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.
Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3122, a PARP1 inhibitor designed for treating advanced malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug shows promise due to its high selectivity and ability to penetrate the blood-brain barrier, potentially offering new treatment options for intracranial tumors. The acceptance of this application marks a significant step for the company, as there are currently no approved drugs worldwide targeting the same mechanism, positioning Sino Biopharmaceutical as a potential leader in this niche market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. The company focuses on the development of innovative drugs, particularly targeting advanced malignant tumors.
YTD Price Performance: 131.74%
Average Trading Volume: 171,317,138
Technical Sentiment Signal: Buy
Current Market Cap: HK$131.6B
Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.